Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Clomiphene citrate Clear all
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 3 Interventional

Treatment of Infertility in Women With Polycystic Ovary Syndrome

NCT00068861
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility, Pregnancy
Interventions
metformin XR, clomiphene citrate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2007 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 2 Interventional

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

NCT01386567
View directory record Official record
Conditions
Hypogonadism, Low Testosterone
Interventions
Androxal (enclomiphene citrate), Testim (topical testosterone)
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 2 Interventional

Clomid in Men With Low Testosterone With and Without Prior Treatment

NCT01904734
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Clomiphene
Drug
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
30 Years to 70 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 8, 2026, 8:59 AM EDT
Withdrawn Not applicable Interventional

SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis

NCT02520505
View directory record Official record
Conditions
Endometriosis, Infertility
Interventions
Supraovulation clomiphene citrate, Timed intercourse, Intrauterine Insemination
Drug · Behavioral · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Traditional Clomiphene Citrate Administration vs. Stair-step Approach

NCT01008319
View directory record Official record
Conditions
Ovulatory Dysfunction, Anovulation, Ovulation Induction
Interventions
clomiphene citrate
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 7, 2018 · Synced Sep 8, 2026, 8:59 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Hypogonadotropic Hypogonadism in Obese Young Males

NCT03245827
View directory record Official record
Conditions
Hypogonadism, Hypogonadotropic
Interventions
Clomiphene, Placebo
Drug
Lead sponsor
Sandeep Singh Dhindsa, M.D., F.A.C.E
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 8, 2026, 8:59 AM EDT
Active, not recruiting Phase 3 Interventional

FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea

NCT05364008
View directory record Official record
Conditions
Leiomyoma, Uterine
Interventions
Green Tea Extract, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

NCT01739595
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
enclomiphene citrate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Mobile, Alabama • Little Rock, Arkansas • Rancho Cucamonga, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women

NCT01340521
View directory record Official record
Conditions
Infertility
Interventions
Clomiphene Citrate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 1994
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization

NCT02865681
View directory record Official record
Conditions
Infertility
Interventions
Menopur, Synarel, HCG trigger, Clomiphene citrate, Letrozole
Drug
Lead sponsor
New Hope Fertility Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 8, 2026, 8:59 AM EDT
Not listed Not applicable Interventional

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

NCT04447872
View directory record Official record
Conditions
Infertility, Diminished Ovarian Reserve, IVF
Interventions
Timing of injectable gonadotropins
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993212
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
8
States / cities
Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 8, 2026, 8:59 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Androxal in Male Infertility

NCT02160704
View directory record Official record
Conditions
Infertility
Interventions
Enclomiphene citrate, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 35 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two Formulations of Androxal

NCT01984398
View directory record Official record
Conditions
Bioequivalence
Interventions
12.5 mg Androxal Formulation A, 12.5 mg Androxal Formulation B, 25 mg Androxal Formulation A, 25 mg Androxal Formulation B
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

NCT00213148
View directory record Official record
Conditions
Anovulation
Interventions
Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg, Clomiphene Citrate 50 mg, Clomiphene Citrate 100 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal

NCT02169804
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 8, 2026, 8:59 AM EDT
Not listed No phase listed Observational

Relationship of the Microenvironment and Male Fertility

NCT04704141
View directory record Official record
Conditions
Male Infertility, Male Hypogonadism
Interventions
Hormone replacement therapy
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

NCT02651688
View directory record Official record
Conditions
Acquired Hypogonadotropic Hypogonadism, Obesity
Interventions
Placebo, Enclomiphene
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Albany, New York • Garden City, New York • Providence, Rhode Island + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit

NCT02294773
View directory record Official record
Conditions
Infertility
Interventions
Intrauterine Insemination, Clomiphene, Letrozole
Procedure · Drug
Lead sponsor
Midwest Fertility Specialists
Industry
Eligibility
21 Years to 39 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Fort Wayne, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

NCT01923870
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting

NCT03028532
View directory record Official record
Conditions
Sports Drug Abuse, Abuse of Steroids or Hormones
Interventions
Clomid
Drug
Lead sponsor
Stuart Willick
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 8, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

NCT01923857
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 25 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 8, 2026, 8:59 AM EDT